SEARCH

SEARCH BY CITATION

References

  • 1
    Hadziyannis S, Bramou T, Makris A, Moussoulis G, Zignego L, Papaioannou C. Interferon alpha-2b treatment of HBeAg negative/serum HBV-DNA positive chronic active hepatitis type B. J Hepatol 1990; 11: S1336.
  • 2
    Fattovich G, Farci P, Rugge M, et al. A randomized controlled trial of lymphoblastoid interferon-alpha in patients with chronic hepatitis B lacking HBeAg. Hepatology 1992; 15: 5849.
  • 3
    Pastore G, Santantonio T, Milella M, et al. Anti-HBe-positive chronic hepatitis B with HBV-DNA in the serum: response to a 6-month course of lymphoblastoid interferon. J Hepatol 1992; 14: 2215.
  • 4
    Lampertico P, Del Ninno E, Manzin A, et al. A randomized controlled trial of a 24-month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum. Hepatology 1997; 26: 16215.
  • 5
    Manesis EK, Hadziyannis SJ. Interferon α treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B. Gastroenterology 2001; 121: 1019.
  • 6
    Lok AS, Heathcote EJ, Hoofnagle JH. Management of Hepatitis B 2000 — Summary of a Workshop. Gastroenterology 2001; 120: 182853.
  • 7
    Tassopoulos NC, Volpes R, Pastore G, et al. Lamivudine Precore Mutant Study Group. Efficacy of lamivudine in patients with hepatitis B e antigen-negative hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Hepatology 1999; 29: 88996.
  • 8
    Santantonio T, Mazzola M, Iacovazzi T, Miglietta A, Guastadisegni A, Pastore G. Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine. J Hepatol 2000; 32: 3006.
  • 9
    Rizzetto M, Volpes R, Smedile A. Response of pre-core mutant chronic hepatitis B infection to lamivudine. J Med Virol 2000; 61: 398400.
  • 10
    Liaw YF, Leung NWY, Chang TT, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology 2000; 119: 17280.
  • 11
    Honkoop P, De Man RA, Niesters HGM, Zondervan PE, Schalm SV. Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy. Hepatology 2000; 32: 6359.
  • 12
    Santantonio T, Niro GA, Sinisi E, et al. Lamivudine/interferon combination therapy in anti-HBe positive chronic hepatitis B patients: a controlled pilot study. J Hepatol 2002; 36: 799804.
  • 13
    Perrillo R, Schiff E, Yoshida E, et al. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 2000; 32: 12934.
  • 14
    Schuurman R. State of the art of genotypic HIV-1 drug resistance. Curr Opin Infect Dis 1997; 10: 4804.
  • 15
    Stuyver L, Van Geyt C, De Gendt S, et al. Line probe assay for monitoring drug resistance in hepatitis B virus-infected patients during antiviral therapy. J Clin Microbiol 2000; 38: 7027.
  • 16
    Esteban R. Clinical and histologic outcome of extended lamivudine in patients with HBeAg negative chronic hepatitis. Hepatology 2001; 34: 1097A.
  • 17
    Hadziyannis SJ, Papatheodoridis GV, Dimou E, Laras A, Papaioannou C. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2000; 32: 84751.
  • 18
    Lok AS, Hussain M, Cursano C, et al. Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy. Hepatology 2000; 32: 114553.
  • 19
    Paganin S, Barbon V, Ciancio A, et al. Long-term lamivudine monotherapy in chronic e-antigen negative hepatitis B: efficacy and breakthrough. J Hepatol 2001; 34(Suppl. 1): 134.
  • 20
    Buti M, Cotrina M, Jardi R, et al. Two years of lamivudine therapy in anti-HBe-positive patients with chronic hepatitis B. J Viral Hepat 2001; 8: 2705.